WHO backs wider use of weight-loss medicines, calling obesity chronic disease
THE UN World Health Organisation (WHO) has issued its first guideline on the use of a new class of weight-loss medicines, marking a significant shift in global health policy as obesity rates continue to rise. The guidance focuses on GLP-1 therapies – medicines such as liraglutide, semaglutide andContinue Reading
















